by 30 Technology | Feb 22, 2021 | News
30 Technology enters into a strategic Licencing Agreement to develop new treatments for multi-drug resistant tuberculosis Thirty Technology joins the fight against antibiotic resistant infection. London, UK, 22 February 2021. Thirty Holdings Limited (“30 Technology”)...
by 30 Technology | Feb 19, 2021 | News
30 Technology launches a critical clinical trial of RESP301 in cystic fibrosis patients with serious lung infections RESP301 to combat antibiotic resistant/refractory infection in people with cystic fibrosis London, UK, 19 February 2021. Thirty Respiratory (“30...
by 30 Technology | Jan 15, 2021 | News
Thirty Respiratory receives approval for multicentre post-exposure clinical trial of RESP301 to prevent transmission of COVID-19 in the community Break-through new treatment to protect people at risk from COVID-19 London, UK, 15 January 2021. Thirty Respiratory (“30...
by 30 Technology | Dec 18, 2020 | News
30 Technology gets the go-ahead for multicentre clinical trial (CORVIS) in the UK of RESP301 in patients with COPD and viral exacerbations, including COVID-19 New treatment to protect lung disease patients from COVID-19 London, UK, 18 December 2020. Thirty Respiratory...
by 30 Technology | Oct 22, 2020 | News
30 Technology announces first patients enrolled in UK clinical trial (NOCoV2) for the treatment of COVID-19 London, UK, 22 October 2020. Thirty Respiratory Ltd (“30 Technology”) announced today that the first patients have been enrolled in the multicentre Phase 2/3...
by 30 Technology | Jun 18, 2020 | News
Thirty Respiratory gets Regulatory Approval to start international, open-label, randomised, multi-centre Phase 2/3 trial of RESP301 in patients hospitalised with COVID-19 London, UK, 18 June 2020. Thirty Respiratory Limited* a world-leader in Nitric Oxide medical...
Recent Comments